Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066386
Filing Date
2025-05-08
Accepted
2025-05-08 07:25:17
Documents
62
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dyn-20250331.htm   iXBRL 10-Q 2365125
2 EX-10.3 dyn-ex10_3.htm EX-10.3 65517
3 EX-10.4 dyn-ex10_4.htm EX-10.4 79951
4 EX-10.5 dyn-ex10_5.htm EX-10.5 78516
5 EX-31.1 dyn-ex31_1.htm EX-31.1 13344
6 EX-31.2 dyn-ex31_2.htm EX-31.2 12774
7 EX-32.1 dyn-ex32_1.htm EX-32.1 7133
8 EX-32.2 dyn-ex32_2.htm EX-32.2 6952
9 GRAPHIC img74267661_0.jpg GRAPHIC 51487
10 GRAPHIC img75191182_0.jpg GRAPHIC 18150
  Complete submission text file 0000950170-25-066386.txt   8072937

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dyn-20250331.xsd EX-101.SCH 846782
64 EXTRACTED XBRL INSTANCE DOCUMENT dyn-20250331_htm.xml XML 1352261
Mailing Address 1560 TRAPELO ROAD WALTHAM MA 02451
Business Address 1560 TRAPELO ROAD WALTHAM MA 02451 (781) 786-8230
Dyne Therapeutics, Inc. (Filer) CIK: 0001818794 (see all company filings)

EIN.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39509 | Film No.: 25923865
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)